Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Shares Outstanding (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Shares Outstanding for 6 consecutive years, with $682.2 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Shares Outstanding fell 7.69% year-over-year to $682.2 million, compared with a TTM value of $682.2 million through Jun 2025, down 7.69%, and an annual FY2025 reading of $695.9 million, down 13.73% over the prior year.
  • Shares Outstanding was $682.2 million for Q2 2025 at Roivant Sciences, down from $695.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $806.7 million in Q1 2024 and bottomed at $651.6 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $723.2 million, with a median of $712.0 million recorded in 2022.
  • The sharpest move saw Shares Outstanding rose 13.69% in 2023, then decreased 13.73% in 2025.
  • Year by year, Shares Outstanding stood at $692.0 million in 2021, then increased by 5.03% to $726.8 million in 2022, then grew by 10.74% to $804.9 million in 2023, then decreased by 10.59% to $719.6 million in 2024, then fell by 5.2% to $682.2 million in 2025.
  • Business Quant data shows Shares Outstanding for ROIV at $682.2 million in Q2 2025, $695.9 million in Q1 2025, and $719.6 million in Q4 2024.